Navigation Links
SCI patients treated with own olfactory ensheathing cells realize neurologic improvement
Date:6/28/2013

Putnam Valley, NY. (June 28 2013) A team of researchers in Poland who treated three of six paraplegics with spinal cord injury using transplanted olfactory ensheathing cells found that the three treated patients showed neurological improvement and no adverse effects while the three control patients who did not receive transplants saw no improvement.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0799tabakow.

"Most accepted treatments for spinal cord injury focus on techniques of early neuro-protection aimed at maximum prevention of secondary spinal cord injury and methods to stimulate plasticity in the central nervous system," said study corresponding author Dr. Pawel Tabakow of the Department of Neurosurgery, Wroclaw Medical University in Wroclaw, Poland. "These measures have helped patients with incomplete spinal injury, but results in patients with complete spinal injury remained limited."

According to the researchers, among the various kinds of neurotrophic cells being tested for transplantation to treat spinal cord injury, OECs deserve "special attention" because they are unique in their natural ability to stimulate regrowth of lesioned axons and "evoke long-distance axon regeneration and subsequent recovery of locomotion in paralyzed limbs."

The researchers noted specifically several laboratory studies using animals modeled with spinal cord injury where OECs derived from the olfactory mucosa have been found to stimulate the regrowth of neural nerves when transplanted into laboratory rats with paralyzed limbs. In those studies they found evidence of restored breathing, locomotion and climbing behavior in the animals.

In a phase one of this non-randomized controlled study, the team of researchers treated the three patients with transplanted self-donated (autologous) OECs and fibroblasts isolated from olfactory mucosa combined with "intense" neuro-rehabilitation. They found the treatment "safe and feasible" one year after transplantation. There was no evidence of neurological deterioration, neuropathic pain, neuroinfection or tumor growth, wrote the researchers.

"Neurophysiological examinations showed improvement in spinal cord transmission and activity of lower extremity muscles in the surgically treated patients, but not in patients receiving only neuro-rehabilitation," they said.

"We consider that the transplantation of OECs was the main factor contributing to the neurologic improvements in the three transplanted patients," said Dr. Tabakow. "Among the possible mechanisms for improvement is that the transplanted OECs may have mediated some restitution along white matter tracts in these patients."

The researchers added that the modest improvements in neurological function occurred against a "background of intense neuro-rehabilitation, which is probably needed for the improvements, although the experience of the control patients indicated that this in itself is not sufficient."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related medicine news :

1. Acid reflux surgery could help prevent rejection in lung transplant patients
2. Surgeons report melanoma recurs after 10 years in more than 6 percent of patients
3. Lowering costs for higher-cost medicare patients through better outpatient care may be limited
4. Nurse practitioners can boost quality of care for older patients with chronic conditions
5. PET-CT improves care of limited-stage small-cell lung cancer patients
6. hCG Treatments / Diet Doc hCG Diets and Weight Loss Plans Offers New hCG Diet Plans to Help Patients Avoid Unsightly Stretch Marks With Supervised Fast Weight Loss
7. New Dental Plan Makes Dental Care More Affordable for Laura Torrado’s and Dr. Shawn Sadris' Patients
8. RSNA: Exercise Benefits Patients with Type 2 Diabetes
9. Exercise benefits patients with type 2 diabetes
10. Health Insurance for Patients with Mental Illness and Substance Use
11. Jackson, MS Periodontist, Dr. Roger Parkes Brings Gum Disease Patients the FDA-cleared Laser Gum Disease Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 2017 , ... Miro is the ultimate smart media center that offers a ... TV shows and much more apps for user exploration. Its innovative acoustic design with ... 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi connection ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... 2017 , ... IndustryArchive.Org . is announcing a new way for B2B ... now only pay for B.A.N.T. quality sales leads based on the Sellers decision to ... new reality that B2B buyers are controlling the sales process via the Internet and ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... RGN-137, GtreeBNT Co., Ltd., received a positive response ... clinical trial design for RGN-137 to treat epidermolysis ... gel that incorporates Thymosin beta 4 ("Tß4") as ...
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
Breaking Medicine Technology: